News Category: Presentations
EAU 2025: Dr. Lerner Presents Safety and efficacy of Bel-sar (AU-011), a Virus-like-Drug-Conjugate (VDC) in patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Retina Society 2024: Dr. Kim Presents Final Results of a Phase 2 Trial of Suprachoroidal Administration of Bel-sar for Choroidal Melanoma
ARVO 2024: Dr. Ma Presents Preclinical Belzupacap Sarotalocan Data for Cancers of the Ocular Surface
Treatment of conjunctival melanoma cell lines with Bel-Sar induces immunogenic cell death
AAO 2023: Dr. Shields Presents Phase 2 SC Belzupacap Sarotalocan Data
A Phase 2 Trial of Belzupacap Sarotalocan, a Targeted Investigational Therapy for Choroidal Melanoma via Suprachoroidal Administration
IPVC 2023: Dr Kines Presents cVDC Data
A novel immunotherapy for the treatment of HPV+ tumors based on a chimeric Virus-like Drug Conjugate
AACR 2023: Dr. Kines Presents cVDC Data
A novel chimeric virus-like drug conjugate for the potential treatment of HPV+ tumors
ARVO 2023: Dr. Ma Presents Preclinical Belzupacap Sarotalocan Data
The role of pigmentation in tumor treatment with virus-like drug conjugate belzupacap sarotalocan (AU-011) in an vitro and vivo model
Macula Society 2023: Dr. Kim Presents Phase 2 SC Safety Belzupacap Sarotalocan Data
A Phase 2 Trial of Belzupacap Sarotalocan (AU-011): An Investigational Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration
SUO 2022: Dr. Shore Presents Trial in Progress Phase I NMIBC Data
A Phase 1, Open-Label Trial to Determine Feasibility and Safety of Intramural Injection of Belzupacap Sarotalocan (AU-011) in Non-Muscle Invasive Bladder Cancer (NMIBC)